Please ensure Javascript is enabled for purposes of website accessibility

Why BioXcel Therapeutics Is Down Sharply This Week

By Cory Renauer – Nov 19, 2021 at 9:56AM

Key Points

  • BioXcel is a clinical-stage biotech that could begin marketing its first new drug in January.
  • A Wall Street analyst downgraded BioXcel stock this week over concerns its lead candidate, BXCL501, will be tough to sell if approved by the FDA.
  • BXCL501 is a sublingual form of a powerful analgesic first approved in 1999 called dexmedetomidine.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A double downgrade from an analyst on Wall Street is causing investors to think twice about the company's first new drug launch.

What happened

Shares of BioXcel (BTAI 2.24%), a pre-commercial stage biopharmaceutical company, are under pressure this week. A double downgrade from Goldman Sachs analyst Corinne Jenkins from buy to sell has investors thinking twice about a potential new drug launch that could begin in early 2022. From the market's close last Friday through 9:32 a.m. ET today, the stock is down 27.3%. 

So what 

The Food and Drug Administration (FDA) is currently reviewing a new drug application for BioXcel's lead candidate, BXCL501 for acute treatment associated with schizophrenia and bipolar disorders. The agency is expected to announce an approval decision on or before Jan. 5, 2022.

Investor looking at stocks on a computer.

Image source: Getty Images.

BXCL501 is a new sublingual formulation of an anesthetic drug called dexmedetomidine. Approval is widely expected because during clinical trials treatment with BXCL501 rapidly reduced agitation for patients with bipolar disorders and schizophrenia without causing any serious side effects.

On Nov. 15, Jenkins downgraded BioXcel over concerns that BXCL501 will only be available in the hospital setting. Small, independent drugmakers that launch new drugs without help from a big pharma partner have a strong tendency to underperform expectations. Pricy new drugs that are only administered to hospitalized patients are especially difficult to sell.

Now what

Because BXL501 is a powerful sedative and analgesic, the FDA is likely to require the presence of trained professionals to administer it. Jenkins didn't state why she didn't realize BXCL501 would become a hospital drug until recently. For over 20 years we've known that overdosage with dexmedetomidine slows down heartbeats and can even cause cardiac arrest.

While BXCL501 probably can't generate enough sales to drive profitability for BioXcel, investors can look forward to a growing pipeline. The company's next candidate, BCLX502, is intended for long-term use by patients with chronic agitation due to dementia.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.